The neuropathology of Alzheimer's disease (AD) and other tauopathies is characterized by filamentous deposits of the microtubule-associated protein tau, but the relationship between tau polymerization and neurotoxicity is unknown. Here, we examined effects of filamentous tau on fast axonal transport (FAT) using isolated squid axoplasm. Monomeric and filamentous forms of recombinant human tau were perfused in axoplasm, and their effects on kinesin-and dyneindependent FAT rates evaluated by video microscopy. While perfusion of monomeric tau at physiological concentrations showed no effect, tau filaments at the same concentrations selectively inhibited anterograde (kinesin-dependent) FAT, triggering the release of conventional kinesin from axoplasmic vesicles. Pharmacological experiments indicated that the effect of tau filaments on FAT is mediated by protein phosphatase 1 (PP1) and glycogen synthase kinase-3 (GSK-3) activities. Moreover, deletion analysis suggested that these effects depend on a conserved 18-amino acid sequence at the amino terminus of tau. Interestingly, monomeric tau isoforms lacking the C-terminal half of the molecule (including the microtubule binding region) recapitulated the effects of full-length filamentous tau. Our results suggest that pathological tau aggregation contributes to neurodegeneration by altering a regulatory pathway for FAT.
INTRODUCTION
Tau is a microtubule-associated protein (MAP) involved in microtubule dynamics and maintenance (Amos and Schlieper 2005) , and insoluble filamentous tau aggregates form in Alzheimer's disease (AD) and several other neurodegenerative tauopathies (reviewed in (Gamblin et al. 2003a) . Despite the strong positive correlation between the appearance of filamentous tau and neuronal dysfunction (reviewed in ), no toxic mechanism has been directly tied to these structures, and as a result the toxicity of tau filaments remains a subject of debate (King 2005) .
In AD, degenerating neurons exhibit alterations in synaptic function (Bell and Claudio Cuello 2006; Yoshiyama et al. 2007) , the appearance of neuritic varicosities, and the mislocalization of various membrane-bound organelles (MBOs), all of which indicate that intracellular transport is disrupted in this disease (reviewed in (Morfini et al. 2002a) . Given these observations, and the central role of tau in AD pathology, a number of investigators have explored the effects of monomeric tau on microtubule-dependent fast axonal transport (FAT).
Although reports have been published arguing both for (Ebneth et al. 1998; Seitz et al. 2002; Vershinin et al. 2007) , and against (Morfini et al. 2007a ) the idea that high levels of soluble tau can reduce anterograde FAT by interfering with the attachment of the molecular motor kinesin, there is no evidence that such levels of tau are seen in normal or pathological neurons.
Remarkably, even though the hallmark of AD and other tauopathies is the presence of intracellular tau filaments, the biological effects of filamentous tau on FAT have not been assessed previously.
In this paper, we examined the effects of tau filaments on FAT using isolated squid axoplasm. Whereas at low, physiologically relevant, ratios of tau to tubulin, monomeric tau has no effect, tau filaments selectively inhibit anterograde, conventional kinesin-dependent fast axonal transport (FAT). Furthermore, deletion experiments indicate that this effect requires the first 18 a.a. at the amino terminus of tau, which becomes abnormally exposed upon polymerization. Consistent with this notion, monomeric tau isoforms lacking the microtubulebinding region (MTBR) and the C-terminus mimicked the effect of tau filaments on FAT.
Finally, we show that tau filaments do not act at the microtubule surface, but rather inhibit anterograde FAT by activating protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK-3). Taken together, our findings reveal a novel gain-of-function mechanism by which the formation of tau filaments may play a critical role in AD pathogenesis.
MATERIALS AND METHODS

Reagents:
CREBpp was synthesized and purified (95%) by New England Peptide (Gardner, MA). Inhibitor-2 (I-2), SB203580, and okadaic acid were purchased from Calbiochem (San Diego, CA). Arachidonic acid (AA; Cayman Chemical, Ann Arbor, MI) was stored at -20°C, and working solutions were prepared in 100% ethanol immediately prior to use. Mammalian protease inhibitor cocktail was from Sigma (St. Louis, MO). ING-135 was synthesized as described previously (Kozikowski et al. 2007 ).
Recombinant Proteins:
The full-length tau used in this study (hTau40) corresponds to the longest isoform in adult human brain, containing 441 amino acids and four microtubule-binding repeats (MTBRs). K23 is a tau construct lacking both alternatively-spliced N-terminal exons as well as all four MTBRs. Tau6D and Tau6P are tau isoforms lacking the MTBR region and the Cterminus of canonical tau. The alternative splicing that generates these isoforms occurs in exon 6, and introduces a unique 11 amino acid sequence followed by a stop codon. The specific 11 amino acids vary depending on whether the splice site is proximal or distal to the beginning of exon 6 (Luo et al. 2004 ). Tau6D and Tau6P isoforms were generated by restriction digestion and ligation of constructs previously described (Luo et al. 2004 ) and hTau40 (Carmel et al. 1996; Gustke et al. 1994) . All other constructs used in this study have been described elsewhere:, Δ2-18 (Gamblin et al. 2003b ), 1-421 (Gamblin et al. 2003c ), K23 (Preuss et al. 1997) . All proteins were expressed in E. coli and purified by means of an N-terminal poly-histidine tag (Abraha et al. 2000; Carmel et al. 1996) .
Immunoblots: Tau constructs were spotted onto nitrocellulose membranes (1 ng/µL, 1 µL per spot), blocked with 5% non-fat dry milk in Tris-buffered saline, pH 7.4, and probed with the monoclonal antibodies Tau12 (2 ng/mL), Tau5 (20 ng/mL), and Tau46.1 (20 ng/mL), which recognize amino acids 9-18, 210-230, and 428-441, respectively (Carmel et al. 1996; Ghoshal et al. 2002; Kosik et al. 1988) . Primary antibody binding was detected with HRP-conjugated antimouse secondary antibody (Vector Laboratories, Burlingame, CA) and ECL developing solution (GE Healthcare, Amersham, UK).
Microtubule-binding Assays: Squid optic lobes were dissected and flash frozen in liquid nitrogen (Morfini et al. 2007a ). 1.5 grams of freshly thawed squid optic lobes was homogenized in 2.5 mL of BRB80 buffer (80 mM Pipes, 1 mM MgCl 2 and 1 mM EGTA) and 1/100 mammalian protease inhibitor cocktail (Sigma, St. Louis, MO), plus phosphatase and kinase inhibitors (Calbiochem, San Diego, CA) as follows: 1/200 phosphatase inhibitor cocktail II, 200 mM sodium orthovanadate, 200 nM mycrocystin RR, 50 nM okadaic acid, 100 nM K252a, 100 nM staurosporine. Squid optic lobe homogenate was prepared at 4 0 C using a glass Dounce homogeneizer. This homogenate was centrifuged at 12,500 x g for 20 min at 4 0 C. The supernatant fraction was transferred to a new tube, and centrifuged at 125,000 x g for 5 min at 4 0 C in a TL100.3 rotor (Beckman, Fullerton, CA). The supernantant (cytosol) was transferred to a new tube, adjusted to 20 µM taxol, and incubated at 37 0 C for 15 min to allow for microtubule polymerization. After this step, 200 µL aliquots of microtubule-containing cytosol were incubated alone, or with htau40, or K23 tau constructs (5 µM final concentration) for 20 min at 37 0 C. Samples were loaded on top of a 60 µL BRB80 buffer plus 20% sucrose cushion and 20
µM taxol using 1.5 mL microcentrifuge tubes, and centrifuged for 5 min at 125,000 x g at 4 0 C using a TLA100.3 rotor (Beckman, Fullerton, CA). Microtubule pellets were resuspended in 200 µL of BRB80. Pellets and supernatant fractions were adjusted to 1X gel loading buffer (GLB) using a 5X GLB stock (0.35 M Tris-HCl pH 6.8, 10% w/v SDS (Sequanal grade, Pierce, Rockford, IL), 36% glycerol, 5% ß-mercaptoethanol, 0.01% bromophenol blue). Membranes were also probed with an antibody against tubulin (DM1a, Sigma) to demonstrate the presence of microtubules in the pellet samples.
Tau Polymerization: Tau polymerization was induced using arachidonic acid as previously described (King et al. 1999) , except that KCl was substituted for NaCl in the polymerization buffer. This substitution did not prevent filament formation (see Fig. 5b-d) . Briefly, tau protein (4 µM) was incubated at room temperature in reaction buffer (50 mM HEPES, pH 7.6, 50 mM KCl, 5 mM DTT) in the presence of 75 µM arachidonic acid (in ethanol vehicle). Samples of soluble tau were prepared for perfusion in the same manner, except that arachidonic acid was excluded from the polymerization buffer. Control mixtures containing AA but lacking tau were prepared in parallel. Final ethanol concentration in all samples was 3.8%.
Electron Microscopy: Polymerization reactions were allowed to proceed for six hours, fixed with 2% glutaraldehyde, spotted onto 300 mesh formvar/carbon coated copper grids (Electron Microscopy Sciences, Hatfield, PA), and negatively stained with 2% uranyl acetate (King et al. 1999 ). Samples were examined using a JEOL JEM-1220 electron microscope at 60kV and 12,000X magnification, and photographs were taken using a MegaScan 794/20 digital camera and DigitalMicrograph software version 3.9.3 (Gatan, Pleasanton, CA).
Squid Axoplasm Motility Assays: Axoplasm from squid giant axons (Loligo pealii; Marine Biological Laboratory, Woods Hole, MA) was extruded as previously described . All proteins and inhibitors were diluted in ATP-supplemented X/2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl 2 , 5 mM EGTA, 1.5 mM CaCl 2 , 0.5 mM glucose, pH 7.2) for perfusion. For experiments involving tau and their controls, reaction mixtures (containing tau alone, tau and AA, and AA alone) were diluted 1:1 in ATP-supplemented X/2 buffer (final tau concentration 2 µM, when present). Motility was analyzed using a Zeiss Axiomat microscope equipped with a 100X, 
Statistical Analysis.
All experiments were repeated at least 3 times. Unless otherwise stated, the data was analyzed by ANOVA followed by post-hoc Student-Newman-Keul's test in order to make all possible comparisons. Comparison of transport data from axoplasm under different conditions was done using a two sample t-test of µ1-µ2 with Datadesk statistical software (Data Description, Inc;
Ithaca, NY). Data was expressed as mean + s.e.m. and significance was assessed at p values as noted.
RESULTS
To evaluate the effect of tau on microtubule-dependent FAT, we used vesicle motility assays in isolated squid axoplasm. In this experimental system, the bi-directional transport of membrane-bound organelles (MBOs) can be directly observed by video-enhanced differential interference contrast (DIC) microscopy. This preparation preserves the ionic strength and complex environment of the cell, and because the axoplasm is isolated from the cell body, nuclear effects can be ignored . Also, the absence of plasma membrane in this preparation allows for the introduction of experimental agents at tightly controlled concentrations (Morfini et al. 2007a ). This system was instrumental in the original discovery of kinesin-1 (Brady 1985) , novel regulatory pathways for FAT (Morfini et al. 2006; Morfini et al. 2004; Morfini et al. 2002b) , and axonal-specific phosphorylation events (Grant et al. 1999) .
Monomeric hTau40 binds to squid microtubules, but does not affect FAT.
Alternative splicing produces six major tau isoforms in the adult human central nervous system. In a previous study, we assayed monomeric tau constructs derived from the shortest tau isoform (352 a.a., hTau23) and established their effects on FAT (Morfini et al. 2007a ). In the present study, we chose to use the longest isoform (441 a.a., hTau40), because of its greater propensity to form filaments (Gamblin et al. 2003a) . Unlike hTau23, hTau40 contains two alternatively-spliced N-terminal exons (E2 and E3) and four microtubule binding repeats (R1-R4). A schematic of each tau construct used in the present study is shown in Fig. 1a .
Previously, we demonstrated that monomeric hTau23 binds to axonal squid microtubules (Morfini et al. 2007a) . To rule out species-related artifacts, we assayed the ability of monomeric hTau40 to interact with endogenous squid microtubules. Microtubule-enriched fractions from squid optic lobe were prepared in the presence or absence of hTau40. Following taxol-induced microtubule assembly, microtubules and associated proteins were sedimented by centrifugation, and the resulting fractions (supernatants and microtubule-enriched pellets) probed with anti-tau antibodies. A tau construct with low binding affinity (K23) was assayed in parallel to control for non-specific sedimentation. As observed previously (Morfini et al. 2007a ), most K23 remained in the supernatant fraction. In contrast, hTau40 was depleted from the supernatant fraction and found in association with the microtubule-enriched pellet fraction (Fig. 1b) , indicating that monomeric hTau40 can bind to endogenous squid microtubules.
Microtubule rigidity is increased when tau binds to the microtubule surface, and this effect is observable even at low, non-saturating tau concentrations (Felgner et al. 1997; Morfini et al. 2007a) . As an additional indicator of hTau40's ability to interact with squid microtubules, we perfused axoplasm with tau and then examined the morphology of microtubules at the axoplasm periphery. In the absence of exogenous tau, many of these microtubules exhibited a curved appearance (Fig. 2a) . However, perfusion of monomeric hTau40 (2 µM) caused peripheral microtubules to acquire a straight, rigid appearance (Fig. 2b) , consistent with binding of hTau40 to the microtubule surface (Morfini et al. 2007a) . Together with the sedimentation assay, these results demonstrate that hTau40 is capable of binding to squid microtubules.
We next examined the effects of monomeric hTau40 on FAT. We perfused axoplasm with hTau40 at 2 µM, which is within the physiological range for neurons (2-5 µM) (Drubin et al. 1985) . The concentration of tubulin in squid axoplasm is 50 µM (Morris and Lasek 1984) , resulting in a tau to tubulin ratio of approximately 1:25. FAT rates measured between 30 and 50 min post-perfusion were pooled and compared to axoplasms perfused with control buffer alone.
As observed for other monomeric tau constructs (Morfini et al. 2007a ), perfusion of hTau40 at 2 µM showed no effect on either anterograde or retrograde FAT (Fig. 3a) , demonstrating that physiological levels of monomeric hTau40 do not impair FAT in this system.
Perfusion of filamentous tau selectively inhibits anterograde FAT.
Recombinant hTau40 forms filaments in vitro when incubated with arachidonic acid (reviewed in (Gamblin et al. 2003a )), and these filaments are morphologically similar to those isolated from Alzheimer's disease neuronal tissue (King et al. 1999) . To determine the effects of filamentous tau on FAT, we perfused hTau40 filaments (2 µM) into squid axoplasm and monitored anterograde and retrograde FAT rates. Unlike monomeric tau, hTau40 filaments inhibited anterograde, kinesin-dependent FAT rates (Fig. 3b, p≤0 .001) when perfused at the same concentration as monomeric hTau40 (2µM). Perfusion of axoplasms with polymerization buffer alone (see Materials and Methods) had no effect on FAT (data not shown), demonstrating that the effects on FAT were due to the presence of filamentous tau. Significantly, retrograde FAT rates remained unaffected, suggesting that the effects of hTau40 filaments on anterograde FAT
were not due to alterations in microtubule integrity. Supporting this idea, htau40 filaments (2 µM) did not produce changes in microtubule morphology when perfused into axoplasm, which also suggests that filamentous tau does not bind to microtubules (Fig. 2c) . Similarly, perfusion of equivalent amounts of polymerization buffer (containing arachidonic acid, but no tau) had no effect on FAT (not shown).
The effect of tau filaments on FAT depends upon the extreme N-terminus of tau
Several studies suggest important functional roles for both the amino and carboxy terminus of tau (Amadoro et al. 2006; Amadoro et al. 2004; Brandt et al. 1995; Lee 2005) , and the study of selected modifications of these domains constitutes an emerging area of interest in AD (Gamblin et al. 2003c; Guillozet-Bongaarts et al. 2005) . To determine whether these domains are involved in FAT inhibition, we assayed two tau constructs, Δ2-18 and 1-421, containing deletions at the extreme amino-and carboxy-terminus, respectively (see Fig. 1a and Fig. 4a ). These deletions do not normally prevent tau from forming filaments (Berry et al. 2003; Gamblin et al. 2003b ). However, the buffer conditions required for axoplasm perfusion (see Materials and Methods) differ from the buffer used in previous tau assembly assays. This led us to evaluate the formation of tau filaments under these experimental conditions using electron microscopic analysis. As shown in Fig. 4b-d, hTau40 , Δ2-18 and 1-421 all form morphologically undistinguishable filaments under these buffer conditions (Fig. 4b-d) .
We then evaluated the effects of Δ2-18 and 1-421 filaments on FAT. Axoplasms perfused with monomeric hTau40 (2 µM) were used as an experimental control, because this treatment results in FAT rates that are indistinguishable from control buffer alone (see Fig. 3a ).
Filaments composed of hTau40 (hTau40 F) and 1-421 (1-421 F) significantly reduced anterograde FAT rates, compared to hTau40 monomer (hTau40 M; *p≤0.0001 by a two-sample t test). In contrast, Δ2-18 filaments (Δ2-18 F) had no effect on FAT (Fig. 5a ). Retrograde transport was unaffected in all conditions (Fig. 5b) . These results suggest that the first 18 a.a. of tau are necessary for the inhibitory effect of tau filaments on anterograde FAT. Although the magnitude of the 1-421 filament effect was not as great that of hTau40 filaments in the time period under analysis, the pattern of inhibition was similar (see Supplemental Fig. 1A ) and the effect of 1-421filaments was not significantly different from full-length hTau40 filaments in a ttest. It remains to be determined if the apparent difference is the result of variability in the effective concentration of the two types of filaments, or if some small difference in the structure of the 1-421 filaments affects the presentation of the N-terminus.
Monomeric tau constructs lacking the C-terminal half of the protein recapitulate the effects of tau filaments on FAT.
Results from deletion experiments above suggested that the first 18 a.a. at the amino terminus of tau are required to elicit the inhibitory effect of tau filaments on FAT. However, various full-length tau constructs including the amino terminal 18 a.a. domain do not affect FAT when perfused in monomeric, soluble form (Fig 2 and (Morfini et al. 2007a) ), suggesting this domain is abnormally exposed in filamentous hTau40. Supporting this idea, biochemical studies identified a intramolecular interaction between the amino and C-terminus of monomeric tau constructs (Horowitz et al. 2006; Jeganathan et al. 2006 ). These observations led us to evaluate the effect of endogenous tau isoforms lacking the C-terminal half of the protein on FAT. These isoforms, Tau6P and Tau6D, are the products of two cryptic splice sites in exon 6 (see Fig. 1a ).
They are identical to canonical tau from amino acids 1-144, at which point splicing introduces a unique 11 amino acid sequence followed by a stop codon. The specific 11 amino acids differ depending on whether the splice site is proximal or distal to the beginning of exon 6 (Luo et al. 2004 ). Tau6P and Tau6D terminate prior to the MTBR region, and so are not expected to interact with microtubules (Lee et al. 1989) or form filaments (Abraha et al. 2000; von Bergen et al. 2000) . When axoplasm was perfused with monomeric Tau6P or Tau6D (2 µM), anterograde FAT was inhibited (p ≤ 0.0001), but retrograde transport remained unchanged. Since the effects of these two isoforms were indistinguishable, data from Tau6P and Tau6D were pooled (Fig. 6 ).
The inhibitory effect of these tau isoforms was indistinguishable from that of hTau40 filaments, indicating that the amino terminus of tau is sufficient to trigger FAT inhibition (see Discussion).
The effects of tau filaments on FAT are mediated by GSK-3 activity.
The effect of tau filaments and monomeric 6P/6D tau isoforms on anterograde FAT raised questions about the underlying molecular mechanisms. The effect of tau filaments on FAT is unlikely to be due to steric hindrance of kinesin by tau at the microtubule surface, because filamentous tau is not expected to bind to microtubules (Fig. 2C ) and Tau6P/6D isoforms lack a MTBR domain. Instead, we suspected that FAT inhibition might occur through one of the signaling pathways that regulate the activity of the major anterograde motor in this system, conventional kinesin Several axonal kinases have been identified that play a role in regulating conventional kinesin-dependent FAT, including JNK (Morfini et al. 2006) , and GSK-3 (Morfini et al. 2002b) kinases. JNK phosphorylates kinesin heavy chains (KHCs), which inhibits kinesin-1 binding to microtubules and results in reduced anterograde FAT (Morfini et al. 2006 ). The effects of abnormal JNK activation can be blocked by SB203580 (Morfini et al. 2006 ), a pharmacological inhibitor that acts on JNK2/3 and other members of the stress-activated protein kinase (SAPK)/JNK family (Coffey et al. 2002; Morfini et al. 2006) . To determine whether tau filaments inhibit anterograde FAT through a mechanism involving JNK activation, we coperfused tau filaments with SB203580 (5 µM). Co-perfusion of tau filaments with SB203580 did not block the effect of tau filaments on FAT ( Fig. 7c ; different from soluble tau at p≤0.001), indicating this effect is independent of JNK and other SAPK/JNK kinases (i.e., p38s).
To evaluate whether tau filaments inhibit anterograde FAT through a mechanism involving GSK-3 activation, we co-perfused hTau40 filaments (2 µM) with cAMP response element-binding protein phosphopeptide (CREBpp; 0.5 mM). While many kinases phosphorylate intact CREB protein, the peptide fragment employed here (KRREILSRRPpSYR) is selectively phosphorylated by GSK-3, and therefore acts as a competitive inhibitor of other GSK-3 substrates (Wang et al. 1994b ). Perfusion of CREBpp in squid axoplasm alone has no effect on FAT, although it effectively blocks the effects of active GSK-3 on kinesin-1-based motility (Morfini et al. 2004; Morfini et al. 2002b ). Remarkably, co-perfusion of tau filaments and CREBpp blocked tau filament-induced effects on FAT (Fig. 7a) , suggesting that the effects of the filaments are dependent on GSK-3 activation. CREBpp also blocked the effects of 1-421 tau filaments, indicating that these filaments act through the same mechanism as filaments of full-length hTau40 (see Supplemental Figure 1 ).
To confirm that GSK-3 activity is required for tau filaments to inhibit kinesin-dependent FAT, we co-perfused tau filaments with the lithium mimetic ING-135 (100 nM), a highly specific inhibitor of GSK-3 (Kozikowski et al. 2007 ) (for the structure of this compound in complex with GSK-3β, see Supplemental Figure 2 ). As with CREBpp, co-perfusion with ING-135 blocked the effect of tau filaments (Fig. 7b) , and perfusion of ING-135 alone had no effect on FAT (data not shown). Together, these results suggest that the effect of tau filaments on anterograde FAT involves activation of axonal GSK-3.
Phosphorylation of kinesin light chains (KLCs) by GSK-3 triggers the chaperonedependent dissociation of kinesin-1 from its cargo (Morfini et al. 2002b; Pigino et al. 2003) . To determine whether tau filaments induce the dissociation of kinesin-1 from cargo, we obtained "sister" axoplasms from individual animals and treated them with monomeric or filamentous hTau40 (2 µM). For comparison, we treated other axoplasm pairs with control buffer or with recombinant, active GSK-3β. After 40 min of incubation, we isolated axoplasmic vesicle fractions and evaluated kinesin-1 levels with an antibody against kinesin heavy chains (KHCs).
Antibodies recognizing the synaptic integral membrane protein SNAP-25 served as a control for equal vesicle protein loading. The recovery of SNAP-25, kinesin-1 and dynein from vesicles was blocked by addition of 0.1% Triton X-100 to axoplasm homogenates prior to centrifugation, confirming the membranous nature of this fraction (not shown). Perfusion of either filamentous tau or active GSK-3β resulted in ≈50% decrease in the amount of kinesin-1 associated with vesicles relative to monomeric tau or control buffer, respectively (p≤0.05 for filamentous tau).
In contrast, levels of dynein intermediate chain were unaffected (Fig. 8 ). These results demonstrate that both tau filaments and GSK-3 selectively inhibit anterograde FAT by leading to dissociation of conventional kinesin-1, but not dynein, from its transported vesicular cargo.
PP1 activity mediates the inhibitory effect of tau filaments on FAT
GSK-3 is inactive when phosphorylated (Wang et al. 1994a) , and can be activated by axonal phosphatases (Morfini et al. 2004; Wang et al. 1994a ). This prompted us to evaluate whether the inhibitory effects of tau filaments involve the activity of axoplasmic phosphatases.
To this end, we co-perfused axoplasm with tau filaments and okadaic acid (100 nM). Okadaic acid inhibits two major serine-threonine phosphatases, namely protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A). Concentrations of okadaic acid alone up to 1 µM have no effect on FAT (Bloom et al. 1993) . Remarkably, okadaic acid blocked the effect of tau filaments on FAT (Fig. 9a) , suggesting that tau filament-mediated inhibition of anterograde FAT involves the activity of a major serine-threonine phosphatase. To distinguish between PP1 and PP2A activity, we co-perfused filaments with 50 nM inhibitor-2 (I-2). I-2 selectively inhibits PP1, but has no effect on PP2A, even at micromolar concentrations (Cohen 1991) . When co-perfused with tau filaments, I-2 prevented FAT inhibition (Fig. 9b) , suggesting that axonal PP1 activity mediates the effect of tau filaments on FAT.
DISCUSSION
We have demonstrated that hTau40 filaments selectively impair anterograde FAT in isolated axoplasm, whereas monomeric hTau40 has no effect at the same concentration. Our results provide a novel link between tau aggregation and neuronal dysfunction, and identify a specific gain of function mechanism conferred by the aggregation process. Further, our studies suggest that inhibition of kinesin-1-based motility represents an important pathogenic event in AD and other tauopathies.
We have previously described a signaling pathway that regulates conventional kinesinbased motility. In this pathway, increased PP1 activity results in the dephosphorylation and activation of axonal GSK-3 (Morfini et al. 2004 ). Activated GSK-3 phosphorylates kinesin light chains (KLCs), prompting a chaperone-dependent dissociation of kinesin-1 and cargo (Morfini et al. 2004; Morfini et al. 2002b) . Results presented here suggest that tau filaments inhibit anterograde FAT by triggering this pathway (Fig. 10) . It is possible that tau filaments directly activate PP1 in this cascade, since tau reportedly binds to PP1 and stimulates its activity (Liao et al. 1998 ). However, more work is necessary to determine whether tau filaments act directly on PP1, or if additional intermediate components remain undiscovered. Additionally, some feedback from GSK-3 is conceivable, since GSK-3 is a major tau kinase that can also bind directly to tau (Sun et al. 2002) , and is reported to be abnormally activated in AD (Ferrer et al. 2005 ).
We demonstrated that the inhibitory effect of tau filaments on FAT requires the extreme amino terminus of the protein. A pivotal role for this part of the protein is consistent with studies in other experimental systems. For example, overexpression of tau amino terminus induces cell death in cultured neurons through a mechanism involving abnormal kinase activity (Amadoro et al. 2006; Amadoro et al. 2004) , and expression of the N-terminus of tau induced microtubule disassembly in cells exposed to beta-amyloid (King et al. 2006) . Immunological studies indicate that loss of the N-terminus is an early event in the maturation of tau fibrillar lesions in AD (Horowitz et al. 2004) . Our results suggest that such cleavage events may modulate the toxicity of filamentous tau on FAT. The amino terminus is also the site of AD-related phosphorylation (Lee et al. 2004 ) and nitration (Reynolds et al. 2006 ) events, and of the FTDP-17-associated mutations R5L (Poorkaj et al. 2002) and R5H (Hayashi et al. 2002) . Analysis of how these modifications influence the effects of tau filaments on FAT may provide further insights into disease progression.
Although hTau40 monomer had no effect on FAT at the concentrations tested, monomers of Tau6P and Tau6D inhibited anterograde FAT as effectively as hTau40 filaments. This result demonstrates that the N-terminus of tau is sufficient to produce the observed effects on FAT, since these isoforms lack the MTBR region and the C-terminal tail of canonical tau.
Additionally, it raises the question of why hTau40 monomer failed to show the same inhibitory effect, even though it contains an intact amino terminus. Although monomeric hTau40 was first thought to exist in an extended conformation (Schweers et al. 1994; Syme et al. 2002) , recent evidence suggests that tau in solution adopts a globally folded conformation in which the Nterminus folds in close proximity to the C-terminus (Horowitz et al. 2006; Jeganathan et al. 2006) . It is possible that this conformation shields the extreme amino terminus, thus preventing hTau40 monomer from inhibiting FAT. In this scenario, polymerization would freeze hTau40 in a different conformation in which the N-terminus is exposed.
With these results, tau joins a growing list of proteins whose pathogenic forms alter regulatory pathways for FAT. Like tau filaments, AD-associated mutations in presenilin-1 inhibit kinesin-1-based motility through GSK-3 activation (Pigino et al. 2003) , whereas pathogenic forms of androgen receptor and huntingtin inhibit kinesin-1 dependent transport through JNK activation (Morfini et al. 2006) . The current study suggests that AD represents an example of a dysferopathy, where alterations in FAT lead to a dying back neuropathy (Morfini et al. 2007b) , providing further evidence that alterations in regulatory pathways for FAT represent a common pathogenic event in multiple, otherwise apparently unrelated neurodegenerative diseases (Morfini et al. 2002a; Morfini et al. 2005) . pooled data from axoplasms perfused with either Tau6P or Tau6D (2 µM). The N-terminus of both isoforms is identical to that of hTau40, but they lack the MTBR region and the C-terminus.
When perfused as monomer into isolated axoplasm, these isoforms inhibit anterograde FAT.
The effect was not statistically different from inhibition caused by hTau40 filaments. and filamentous tau was significant at p≤0.05 using a two sample t-test of µ1-µ2. Figure 9 . The effect of tau filaments depends upon PP1 activity. The inhibitory effect of tau filaments on FAT was blocked by co-perfusion with (A) the serine-threonine phosphatase inhibitor okadaic acid (100 nM), and (B) the PP1-specific inhibitor I-2 (50 nM). Perfusion of either of these inhibitors alone had no effect on FAT (data not shown). dephosphorylates and activates GSK-3, which subsequently phosphorylates kinesin light chains (KLCs). Phosphorylation of KLCs, promotes a chaperone-mediated detachment of kinesin-1 from its transported cargo. Our results suggest that tau can trigger this cascade when the amino terminus of tau is abnormally exposed in the filamentous form.
